HUTCHMED closes HMPL-A830 license deal with GSK for territories outside China
The licensing agreement covering the KRAS-EGFR antibody conjugate candidate took effect after antitrust clearance, triggering a $110 million upfront payment.
HUTCHMED (China) Limited said on October 21, 2026 that its license agreement with a GSK plc subsidiary for the cancer drug candidate HMPL-A830 has closed. The closing follows HUTCHMED's September 3, 2026 announcement and came after customary closing conditions, including antitrust regulatory reviews, were completed, with the deal structured between HUTCHMED Limited, a subsidiary of HUTCHMED, and the GSK subsidiary.1
Under the agreement, GSK's subsidiary gains rights to develop and sell HMPL-A830 everywhere except mainland China, Hong Kong, Macau and Taiwan.1
HMPL-A830 is described as a first-in-class Antibody-Targeted Therapy Conjugate that pairs a KRAS small molecule inhibitor payload with an antibody targeting EGFR.1 The company noted that colorectal, pancreatic and lung cancers carry the highest rates of KRAS-altered tumors, a population that often has no safe and lasting KRAS treatment option.1 A Phase Ia global trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors began in China and the US in September 2026, registered under NCT07718581.1
On the division of responsibilities, HUTCHMED Limited will run the global Phase I development program, while the GSK subsidiary takes over all later-stage clinical development and commercialization in its licensed territory.1
Financially, HUTCHMED Limited expects to receive the $110 million upfront payment shortly after closing, with potential additional milestone payments tied to development, regulatory and commercial progress totaling up to $1.185 billion, plus tiered royalties on net sales.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.